Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin

Trial Profile

Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacodynamics
  • Acronyms EMEG-E-01
  • Most Recent Events

    • 19 Jun 2017 Planned End Date changed from 1 Jul 2017 to 3 Dec 2018.
    • 19 Jun 2017 Planned primary completion date changed from 1 May 2017 to 3 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top